Recombinant
RabMAb

Anti-Aurora B antibody [EP1009Y] (ab45145)

Reviews (1) Submit a question References (17)

Overview

  • Product name
    Anti-Aurora B antibody [EP1009Y]
    See all Aurora B primary antibodies
  • Description
    Rabbit monoclonal [EP1009Y] to Aurora B
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WB, IHC-P, ICC/IF, IPmore details
    Unsuitable for: Flow Cyt
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human Aurora B aa 1-100 (N terminal). The exact sequence is proprietary.

  • General notes

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab45145 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/50000. Predicted molecular weight: 39 kDa.
IHC-P 1/250 - 1/500.
ICC/IF 1/100 - 1/150.
IP 1/50.
  • Application notes
    Is unsuitable for Flow Cyt.

    • Target

    • Function
      May be directly involved in regulating the cleavage of polar spindle microtubules and is a key regulator for the onset of cytokinesis during mitosis. Component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Phosphorylates 'Ser-10' and 'Ser-28' of histone H3 during mitosis. Required for kinetochore localization of BUB1 and SGOL1. Interacts with INCENP.
    • Tissue specificity
      High level expression seen in the thymus. It is also expressed in the spleen, lung, testis, colon, placenta and fetal liver. Expressed during S and G2/M phase and expression is up-regulated in cancer cells during M phase.
    • Involvement in disease
      Note=Disruptive regulation of expression is a possibile mechanism of the perturbation of chromosomal integrity in cancer cells through its dominant-negative effect on cytokinesis.
    • Sequence similarities
      Belongs to the protein kinase superfamily. Ser/Thr protein kinase family. Aurora subfamily.
      Contains 1 protein kinase domain.
    • Post-translational
      modifications
      Ubiquitinated by different BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complexes. Ubiquitinated by the BCR(KLHL9-KLHL13) E3 ubiquitin ligase complex, ubiquitination leads to removal from mitotic chromosomes and is required for cytokinesis. During anaphase, the BCR(KLHL21) E3 ubiquitin ligase complex recruits the CPC complex from chromosomes to the spindle midzone and mediates the ubiquitination of AURKB. Ubiquitination of AURKB by BCR(KLHL21) E3 ubiquitin ligase complex may not lead to its degradation by the proteasome.
    • Cellular localization
      Nucleus. Chromosome. Chromosome > centromere. Cytoplasm > cytoskeleton > spindle. Localizes on chromosome arms and inner centromeres from prophase through metaphase and then transferring to the spindle midzone and midbody from anaphase through cytokinesis. Colocalized with gamma tubulin in the mid-body.
    • Information by UniProt
    • Database links
      • Alternative names
        • AIK2 antibody
        • AIM-1 antibody
        • AIM1 antibody
        • ARK-2 antibody
        • ARK2 antibody
        • AurB antibody
        • AURKB antibody
        • AURKB_HUMAN antibody
        • Aurora 1 antibody
        • Aurora and Ipl1 like midbody associated protein 1 antibody
        • Aurora kinase B antibody
        • Aurora related kinase 2 antibody
        • Aurora- and Ipl1-like midbody-associated protein 1 antibody
        • Aurora-B antibody
        • Aurora-related kinase 2 antibody
        • Aurora/IPL1 related kinase 2 antibody
        • Aurora/IPL1-related kinase 2 antibody
        • IPL1 antibody
        • PPP1R48 antibody
        • Protein phosphatase 1 regulatory subunit 48 antibody
        • Serine/theronine kinase 12 antibody
        • Serine/threonine protein kinase 12 antibody
        • Serine/threonine-protein kinase 12 antibody
        • Serine/threonine-protein kinase aurora-B antibody
        • STK-1 antibody
        • STK1 antibody
        • STK12 antibody
        • STK5 antibody
        see all

      Images

      • Western blot - Anti-Aurora B antibody [EP1009Y] (ab45145)
        Western blot - Anti-Aurora B antibody [EP1009Y] (ab45145)
        Lanes 1-2 : Anti-Aurora B antibody [EP1009Y] (ab45145) at 1/1000 dilution
        Lanes 3-4 : Anti-Aurora B antibody [EP1009Y] (ab45145) at 1/5000 dilution
        Lanes 5-6 : Anti-Aurora B antibody [EP1009Y] (ab45145) at 1/10000 dilution
        Lanes 7-8 : Anti-Aurora B antibody [EP1009Y] (ab45145) at 1/50000 dilution
        Lanes 9-10 : Anti-Aurora B antibody [EP1009Y] (ab45145) at 1/75000 dilution

        Lanes 1 & 3 & 5 & 7 & 9 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
        Lanes 2 & 4 & 6 & 8 & 10 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate Nocodozole Stimulated

        Lysates/proteins at 10 µg per lane.

        Secondary
        All lanes : Anti-Rabbit IgG VHH Single Domain (HRP) (ab191866) at 1/10000 dilution

        Developed using the ECL technique.

        Performed under reducing conditions.

        Predicted band size: 39 kDa
        Observed band size: 39 kDa


        Exposure time: 8 minutes


        This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab45145 overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP, and visualised using ECL development solution ab133406

      • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Aurora B antibody [EP1009Y] (ab45145)
        Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Aurora B antibody [EP1009Y] (ab45145)
        ab45145 showing positive staining in Normal tonsil tissue.

      • Immunocytochemistry/ Immunofluorescence - Anti-Aurora B antibody [EP1009Y] (ab45145)
        Immunocytochemistry/ Immunofluorescence - Anti-Aurora B antibody [EP1009Y] (ab45145)

        Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized  HeLa (Human epithelial cells from cervix adenocarcinoma cell line) cell lines labeling Aurora B with ab45145 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green).

        Confocal image showing midbody and centromeres staining on Hela cells

        The nuclear counterstain is DAPI (blue).

        Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Loading Control (ab7291) at 1/1000 dilution and Goat Anti-Mouse IgG H&L (Alexa Fluor® 594) preadsorbed (ab150120) at 1/1000 dilution (red).

        The negative controls are as follows:-

        -ve control 1: ab45145 at 1/500 dilution followed by ab150120 at 1/1000 dilution.

        -ve control 2: ab7291 at 1/1000 dilution followed by ab150077 at 1/1000 dilution.

      • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Aurora B antibody [EP1009Y] (ab45145)
        Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Aurora B antibody [EP1009Y] (ab45145)
        Ab45145 staining human Aurora B in human Hodgkin lymphoma by immunohistochemistry using paraffin embedded tissue.
      • Western blot - Anti-Aurora B antibody [EP1009Y] (ab45145)
        Western blot - Anti-Aurora B antibody [EP1009Y] (ab45145)
        Anti-Aurora B antibody [EP1009Y] (ab45145) at 1/50000 dilution + HeLa cell lysate

        Predicted band size: 39 kDa
        Observed band size: 39 kDa

      • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Aurora B antibody [EP1009Y] (ab45145)
        Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Aurora B antibody [EP1009Y] (ab45145)
        ab45145 showing positive staining in Breast carcinoma tissue.

      • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Aurora B antibody [EP1009Y] (ab45145)
        Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Aurora B antibody [EP1009Y] (ab45145)
        ab45145 showing positive staining in Cervical carcinoma tissue.

      • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Aurora B antibody [EP1009Y] (ab45145)
        Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Aurora B antibody [EP1009Y] (ab45145)
        ab45145 showing positive staining in Urinary bladder transitional carcinoma tissue.

      • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Aurora B antibody [EP1009Y] (ab45145)
        Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Aurora B antibody [EP1009Y] (ab45145)
        ab45145 showing positive staining in Lung adenocarcinoma tissue.

      • Other - Anti-Aurora B antibody [EP1009Y] (ab45145)
        Other - Anti-Aurora B antibody [EP1009Y] (ab45145)
        Equilibrium disassociation constant (KD)
        Learn more about KD

        Click here to learn more about KD

      References

      This product has been referenced in:
      • Xie CM  et al. Cardiac glycoside bufalin blocks cancer cell growth by inhibition of Aurora A and Aurora B activation via PI3K-Akt pathway. Oncotarget 9:13783-13795 (2018). Read more (PubMed: 29568394) »
      • Lin J  et al. FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells. Cancer Sci 109:1001-1011 (2018). WB ; Human . Read more (PubMed: 29427543) »
      See all 17 Publications for this product

      Publishing research using ab45145? Please let us know so that we can cite the reference in this datasheet.

      Customer reviews and Q&As

      Show All Reviews Q&A
      Submit a review

      Filter by Application

      Filter by Species

      Filter by Ratings

      Western blot abreview for Anti-Aurora B antibody [EP1009Y]

       Good
      Abreviews
      abreview image
      Application
      Western blot
      Loading amount
      30 µg
      Gel Running Conditions
      Reduced Denaturing (4-12% Bis-Tris gel)
      Sample
      Human Cell lysate - whole cell (U2OS-osteosarcoma)
      Specification
      U2OS-osteosarcoma
      Blocking step
      BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: RT°C
      Read More

      Dr. Carlos le Sage

      Verified customer

      Submitted Jan 21 2014

      Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

      Sign up